Open Access Article
This Open Access Article is licensed under a Creative Commons Attribution-Non Commercial 3.0 Unported Licence

Synthesis of multisubstituted cycloalkenes through carbomagnesiation of strained cycloalkynes

Yuya Tamura , Yasunori Minami , Yoshitake Nishiyama , Yuki Sakata , Fumika Karaki , Takamitsu Hosoya and Suguru Yoshida *
Laboratory of Chemical Bioscience, Institute of Biomaterials and Bioengineering, Tokyo Medical and Dental University (TMDU), 2-3-10 Kanda-Surugadai, Chiyoda-ku, Tokyo 101-0062, Japan. E-mail: s-yoshida.cb@tmd.ac.jp

Received 17th April 2020 , Accepted 19th May 2020

First published on 19th May 2020


Abstract

An efficient synthetic method of seven- and six-membered cycloalkenes through the generation of strained cycloalkynes and following carbomagnesiation is described. Further bond formations of the resulting cycloalkenylmagnesium intermediates with a wide variety of electrophiles enabled us to prepare diverse cycloalkene derivatives including benzoxepine analogs having a fully substituted alkene structure.


Medium-sized ring compounds are of great importance in broad research fields including pharmaceutical sciences and materials chemistry. In particular, constructing condensed medium-sized ring structures having a number of substituents is a significant and challenging issue in synthetic organic chemistry, as shown by the various bioactive arene-fused cycloheptane derivatives such as modulators for estrogen receptor (ER) (Fig. 1A).1–3 Despite the continuous efforts toward developing synthetic methodologies for condensed ring compounds, it is not easy to prepare multisubstituted fused cycloheptanes by conventional methods due to the limited cyclization methods forming a seven-membered structure.4 We herein describe an efficient method to synthesize multisubstituted cycloalkenes involving arene-fused cycloheptenes by carbomagnesiation of transiently generated strained cycloalkynes5–7 and subsequent bond formation with a variety of electrophiles.
image file: d0cc02788j-f1.tif
Fig. 1 Background and design of this study. (A) Bioactive arene-fused cycloheptane derivatives. (B) Catalytic carbomagnesiation of alkynes. (C) Concept of this work.

Transformations via the carbomagnesiation of alkynes catalyzed by transition-metals such as copper and iron have been employed in tetrasubstituted alkene synthesis (Fig. 1B).8 Keeping in mind the versatility of carbomagnesiation and difficulty of cyclization to form seven-membered rings, we envisioned that a wide range of multisubstituted cycloheptenes can be prepared by the carbomagnesiation of transiently generated cycloheptynes followed by further bond formations with electrophiles on the basis of our recent achievements (Fig. 1C). Previously, we have developed an efficient cycloheptyne generation method from 2-(p-tolylsulfinyl)cycloheptenyl triflate (1a) using a phenyl Grignard reagent through sulfoxide–magnesium exchange9 followed by β-elimination, enabling us to prepare a variety of cycloheptene derivatives by cycloaddition with ynophiles including azides.7 The cycloalkyne generation method from easily accessible precursors and potential electrophilicity of angle-strained cycloalkynes6a,h–j,10 motivated us to develop cycloalkene synthesis through the carbomagnesiation of cycloalkynes, which is a challenging issue due to the less polar C–C triple bond and the similar nucleophilicity of the resulting alkenylmagnesium intermediates.

Considering the significance of arene-fused cycloheptene scaffolds, we first attempted the carbomagnesiation of benzene-fused cycloheptyne II from sulfoxide 1b with phenylmagnesium bromide at room temperature (Fig. 2A). After quenching with aqueous ammonium chloride, benzene-fused cycloheptene 2a was obtained in high yield as a single isomer, where the regioisomer 2a′ was not detected.11 This result clearly showed that the phenyl Grignard reagent acted both as an activator to generate cycloheptyne intermediate II and as a nucleophile to form cycloheptenylmagnesium intermediate III. As no catalysts or harsh conditions were required, this transformation was promoted by the inherent reactivity of transient intermediate II with a distorted alkyne configuration.


image file: d0cc02788j-f2.tif
Fig. 2 Carbomagnesiation of in situ generated cycloalkynes. (A) Initial attempt. (B) General scheme. (C) Scope of Grignard reagents. (D) Scope of cycloalkynes. (E) Carbomagnesiation of cycloheptyne. a6.0 equiv. of RMgX was used. b10 equiv. of RMgX was used. c5.0 equiv. of RMgX was used. dTHF was used instead of Et2O as a solvent. See the ESI for details.

A broad range of Grignard reagents participated in the seven- and six-membered cycloalkyne generation and following carbomagnesiation (Fig. 2B). Indeed, benzene-fused cycloheptenes 2b–2i having aryl, alkenyl, and alkyl groups were obtained in moderate to good yields with the simple procedure only by adding the corresponding Grignard reagents at room temperature without any transition-metal catalysis (Fig. 2C). Aryl Grignard reagents bearing an electron-donating or electron-withdrawing substituent at the p- or sterically hindered o-position also facilitated cycloalkyne generation and subsequent regioselective carbomagnesiation, affording benzene-fused cycloheptenes 2b–2e after protonation. In addition, benzene-fused cycloheptenes 2f–2i were also prepared using vinylmagnesium bromide and primary and secondary alkyl Grignard reagents in moderate yields.

Diverse seven- and six-membered cycloalkenes were successfully synthesized by the cycloalkyne generation and carbomagnesiation sequence (Fig. 2D). For example, treatment of benzoxepine-type cycloalkyne precursors, prepared easily from the corresponding ketones, with phenylmagnesium bromide followed by protonation selectively provided various benzoxepine derivatives 3–5 in high yields without damaging the methoxy and bromo groups. It is worth noting that the carbomagnesiation product 6 was prepared in good yield from the corresponding 2-sulfinylcycloalkenyl triflate without alkene isomerization. The reaction of a thiophene-fused cycloheptyne also proceeded smoothly to afford cycloheptene 7 in moderate yield. Furthermore, we succeeded in the generation of benzene-fused cyclohexynes and following carbomagnesiation to furnish 8–10 in low to high yields. In addition, phenylation of cyclohexyne also took place to provide 1-phenylcyclohexene (11) in moderate yield. When cycloheptyne precursor 1a was treated with a p-anisyl Grignard reagent, the following protonation afforded cycloheptene 12 in moderate yield along with a small amount of diene 13 as a byproduct formed by the reaction between alkenylmagnesium intermediate IV and cycloheptyne (I) (Fig. 2E). These results clearly showed that a wide range of cycloalkenylmagnesium intermediates can be prepared from various cycloalkyne precursors and Grignard reagents.

Further bond-formations of the cycloheptenylmagnesium intermediate with a wide variety of electrophiles enabled the selective preparation of benzene-fused cycloheptenes 2j–2r containing fully substituted alkene scaffolds (Fig. 3). Indeed, an intermediate formed from 1b by the treatment with a phenyl Grignard reagent was efficiently trapped with iodine to provide iodoalkene 2j in high yield. The efficiency of iodination was slightly decreased when using bulky o-tolylmagnesium bromide in the first step. Bromination and chlorination were also accomplished by trapping N-bromosuccinimide (NBS) and p-toluenesulfonyl (Ts) chloride12 to form bromide 2l and chloride 2m, respectively. Sulfanylation using thiosulfonates13 took place smoothly affording alkenyl sulfides 2n and 2o in good yields. Successful C–C bond formations with a variety of electrophiles such as carbon dioxide, N,N-dimethylformamide (DMF), and p-chlorobenzaldehyde were achieved to furnish tetrasubstituted alkenes 2p–2r selectively. Of note, the reaction using an aldehyde only afforded ketone 2r probably due to the oxidation by excess aldehyde.14 These results clearly showed that transformations through cycloheptyne generation and carbomagnesiation enable the synthesis of cycloheptenes having a wide variety of functional groups, which are difficult to prepare by conventional methods, in a practical and simple way.


image file: d0cc02788j-f3.tif
Fig. 3 Direct synthesis of disubstituted benzene-fused cycloheptenes. a4.0 equiv. of electrophile was used. b8.0 equiv. of electrophile was used. c10 equiv. of electrophile was used. d5.0 equiv. of electrophile was used.

Accessible cycloalkenes were remarkably expanded by the palladium-catalyzed cross-coupling reactions (Fig. 4).15 For instance, the reaction between cycloheptyne precursor 1b and phenylmagnesium bromide followed by the palladium-catalyzed Kumada–Tamao–Corriu coupling occurred smoothly, affording tetrasubstituted alkene 2s (Fig. 4A). Furthermore, the Mizoroki–Heck reaction between iodoalkene 2j and ethyl acrylate successfully provided diene 2t in high yield (Fig. 5B, upper). Also, alkynylation of iodide 2j by Sonogashira coupling resulted in the synthesis of enyne 2u (Fig. 4B, lower). The transformation involving palladium-catalyzed coupling allowed for the facile preparation of a benzoxepin-type selective ERβ modulator analog 14 (Fig. 4C). Indeed, the synthesis of benzoxepine derivative 14 possessing fluoro, p-hydroxyphenyl, and p-anisyl groups was accomplished by carbomagnesiation of cycloalkyne generated from precursor 1c, followed by iodination and Suzuki–Miyaura cross-coupling, enabling the introduction of different aryl groups in a regioselective manner. Considering the introducible Grignard reagents and the versatility of cross-coupling chemistry, synthesizing not only the reported ERβ modulator through demethylation of the p-anisyl group but also diverse analogs will be realized only by changing the modules.1b


image file: d0cc02788j-f4.tif
Fig. 4 Transformations involving catalytic C–C bond formations. (A) Synthesis of 2s. (B) Alkenylation and alkynylation of 2j. (C) Synthesis of ERβ modulator analog 14. See the ESI for details.

image file: d0cc02788j-f5.tif
Fig. 5 Synthesis of analogs of a tetracyclic bioactive molecule. (A) Synthesis of 15. (B) Synthesis of 16. See the ESI for details. PPA = polyphosphoric acid.

The utility of cycloalkene synthesis via carbomagnesiation of cycloalkynes was showcased by preparing analogs of an anti-cancer tetracyclic compound (Fig. 5). We achieved the efficient synthesis of lactone 15 through o-anisylation of benzene-fused cycloheptyne generated from precursor 1b, followed by carboxylation with carbon dioxide and subsequent condensation, modifying the conditions for the preparation of cytotoxic compounds against cancer cells.3,16 Additionally, a deoxygenated analog 16 was synthesized by PPA-mediated cyclization of carboxylic acid 2p. Taking into account the difficulties to construct condensed skeletons containing a seven-membered ring and fully substituted alkenes, the present method using the convergent cycloalkene synthesis and further cyclization could enable developing bioactive compounds.

In conclusion, we have developed an efficient synthetic method of seven- and six-membered cycloalkenes through cycloalkyne generation, carbomagnesiation, and further bond formations with a wide variety of electrophiles. The carbomagnesiation of strained cycloalkynes disclosed the inherent reactivity of transiently generated cycloalkyne intermediates with a distorted alkyne configuration, which will remarkably expand the synthetic utility of cycloalkynes. Diverse arene-fused cycloheptene derivatives having a fully substituted alkene structure such as analogs of bioactive compounds were efficiently synthesized through this reaction. Further studies to examine the preparable cycloalkenes and expand the introducible nucleophiles instead of Grignard reagents based on the good electrophilicity of transiently generated cycloalkynes clarified in this study are now ongoing.

This work was supported by JSPS KAKENHI Grant Numbers JP19K05451 (C; S. Y.), JP18H02104 (B; T. H.), and JP18H04386 (Middle Molecular Strategy; T. H.); the Naito Foundation (S. Y.); the Japan Agency for Medical Research and Development (AMED) under Grant Number JP19am0101098 (Platform Project for Supporting Drug Discovery and Life Science Research, BINDS); and the Cooperative Research Project of Research Center for Biomedical Engineering.

Conflicts of interest

There are no conflicts to declare.

Notes and references

  1. (a) I. Barrett, M. J. Meegan, R. B. Hughes, M. Carr, A. J. S. Knox, N. Artemenko, G. Golfis, D. M. Zisterer and D. G. Lloyd, Bioorg. Med. Chem., 2008, 16, 9554 CrossRef CAS; (b) N. M. O’Boyle, I. Barrett, L. M. Greene, M. Carr, D. Fayne, B. Twamley, A. J. S. Knox, N. O. Keely, D. M. Zisterer and M. J. Meegan, J. Med. Chem., 2018, 61, 514 CrossRef.
  2. (a) T. Wintermantel, C. Moeller, U. Bothe, R. Nubbemeyer, L. Zorn, D. Kosemund, A. Ter Laak, R. Bohlmann, L. Wortmann and D. Bierer, Bayer Pharma Aktiengesellschaft, WO2011161101, 2011; (b) T. Wintermantel, C. Moeller, U. Bothe, R. Nubbemeyer, L. Zorn, A. Ter Laak, R. Bohlmann and L. Wortmann, Bayer Intellectual Property GmbH, WO2013083568, 2013; (c) L. Zorn, D. Kosemund, C. Möller, H. Irlbaher, R. Nubbemeyer, A. Ter Laak and U. Bothe, Bayer Pharma Aktiengesellschaft, WO2015028409, 2015.
  3. B. Yadagiri, U. D. Holagunda, R. Bantu, L. Nagarapu, C. G. Kumar, S. Pombala and B. Sridhar, Eur. J. Med. Chem., 2014, 79, 260 CrossRef CAS.
  4. For selected reviews, see: (a) J. O. Hoberg, Tetrahedron, 1998, 54, 12631 CrossRef CAS; (b) T. V. Nguyen, J. M. Hartmann and D. Enders, Synthesis, 2013, 845 CAS; (c) K. T. de Oliveira, B. M. Servilha, L. C. Alves, A. L. Desiderá and T. J. Brocksom, in Studies in Natural Products Chemistry, ed. A. Rahman, Elsevier, Oxford, vol. 42, 2014, pp. 421–463 Search PubMed; (d) Y. Hu, M. Bai, Y. Yang and Q. Zhou, Org. Chem. Front., 2017, 4, 2256 RSC.
  5. For selected reviews, see: (a) R. W. Hoffmann, Dehydrobenzene and Cycloalkynes, Academic Press, New York, 1967 Search PubMed; (b) A. Krebs and J. Wilke, Topics Current Chemistry, 1983, vol. 109, 189 Search PubMed; (c) H. Hopf and J. Grunenberg, in Strained Hydrocarbons, ed. H. Dodziuk, Wiley-VCH, Weinheim, 2009, ch. 7 Search PubMed; (d) C. M. Gampe and E. M. Carreira, Angew. Chem., Int. Ed., 2012, 51, 3766 CrossRef CAS.
  6. For selected examples, see: (a) F. Scardiglia and J. D. Roberts, Tetrahedron, 1957, 1, 343 CrossRef CAS; (b) G. Wittig and A. Krebs, Chem. Ber., 1961, 94, 3260 CrossRef CAS; (c) F. G. Willey, Angew. Chem., Int. Ed. Engl., 1964, 3, 138 CrossRef; (d) W. Tochtermann, K. Oppenländer and U. Walter, Chem. Ber., 1964, 97, 1318 CrossRef CAS; (e) W. Tochtermann, K. Oppenländer and U. Walter, Chem. Ber., 1964, 97, 1329 CrossRef CAS; (f) R. Breslow, L. J. Altman, A. Krebs, E. Mohacsi, I. Murata, R. A. Peterson and J. Posner, J. Am. Chem. Soc., 1965, 87, 1326 CrossRef CAS; (g) N. Atanes, S. Escudero, D. Pérez, E. Guitián and L. Castedo, Tetrahedron Lett., 1998, 39, 3039 CrossRef CAS; (h) M. Fujita, Y. Sakanishi, M. Nishii and T. Okuyama, J. Org. Chem., 2002, 67, 8138 CrossRef CAS PubMed; (i) C. M. Gampe and E. M. Carreira, Chem. – Eur. J., 2012, 18, 15761 CrossRef CAS; (j) J. M. Medina, T. C. McMahon, G. Jiménez-Osés, K. N. Houk and N. K. Garg, J. Am. Chem. Soc., 2014, 136, 14706 CrossRef CAS; (k) S. F. Tlais and R. L. Danheiser, J. Am. Chem. Soc., 2014, 136, 15489 CrossRef CAS; (l) T. K. Shah, J. M. Medina and N. K. Garg, J. Am. Chem. Soc., 2016, 138, 4948 CrossRef CAS; (m) Y. Hioki, K. Okano and A. Mori, Chem. Commun., 2017, 53, 2614 RSC; (n) J. V. Chari, F. M. Ippoliti and N. K. Garg, J. Org. Chem., 2019, 84, 3652 CrossRef CAS PubMed; (o) Y. Hioki, T. Yukioka, K. Okano and A. Mori, Asian J. Org. Chem., 2018, 7, 1298 CrossRef CAS; (p) E. R. Darzi, J. S. Barber and N. K. Garg, Angew. Chem., Int. Ed., 2019, 58, 9419 CrossRef CAS; (q) R. Nakura, K. Inoue, K. Okano and A. Mori, Synthesis, 2019, 1561 CAS; (r) Y. Hioki, A. Mori and K. Okano, Tetrahedron, 2020, 76, 131103 CrossRef CAS.
  7. S. Yoshida, F. Karaki, K. Uchida and T. Hosoya, Chem. Commun., 2015, 51, 8745 RSC.
  8. For selected reviews, see: (a) K. Murakami and H. Yorimitsu, Beilstein J. Org. Chem., 2013, 9, 278 CrossRef CAS PubMed; (b) D. S. Müllera and I. Marek, Chem. Soc. Rev., 2016, 45, 4552 RSC.
  9. For selected examples, see: (a) N. Furukawa, T. Shibutani and H. Fujihara, Tetrahedron Lett., 1987, 28, 2727 CrossRef CAS; (b) L. Melzig, C. B. Rauhut, N. Naredi-Rainer and P. Knochel, Chem. – Eur. J., 2011, 17, 5362 CrossRef CAS; (c) S. Yoshida, K. Uchida and T. Hosoya, Chem. Lett., 2014, 43, 116 CrossRef CAS; (d) S. Yoshida, K. Uchida and T. Hosoya, Chem. Lett., 2015, 44, 691 CrossRef CAS; (e) T. Kimura, H. Momochi, K. Moriuchi, T. Katagiri and T. Satoh, Tetrahedron Lett., 2017, 58, 3505 CrossRef CAS.
  10. J.-A. García-López and M. F. Greaney, Chem. Soc. Rev., 2016, 45, 6766 RSC.
  11. Use of phenyllithium instead of phenylmagnesium bromide gave a complex mixture and phenylzinc bromide did not react with 1b.
  12. (a) F. Chemla, I. Marek and J.-F. Normant, Synlett, 1993, 665 CrossRef CAS; (b) W. Lin, O. Baron and P. Knochel, Org. Lett., 2006, 8, 5673 CrossRef CAS PubMed.
  13. P. Mampuys, C. R. McElroy, J. H. Clark, R. V. A. Orru and B. U. W. Maes, Adv. Synth. Catal., 2020, 362, 3 CrossRef CAS.
  14. R. J. Kloetzing, A. Krasovskiy and P. Knochel, Chem. – Eur. J., 2007, 13, 215 CrossRef CAS.
  15. For recent reviews, see: (a) R. Chinchilla and C. Nájera, Chem. Soc. Rev., 2011, 40, 5084 RSC; (b) S. Jagtap, Catalysts, 2017, 7, 267 CrossRef; (c) M. M. Heravi, V. Zadsirjan, P. Hajiabbasi and H. Hamidi, Monatsh. Chem., 2019, 150, 535 CrossRef CAS; (d) S. E. Hooshmand, B. Heidari, R. Sedghi and R. S. Varma, Green Chem., 2019, 21, 381 RSC.
  16. When we attempted a reaction using 2-(p-tolylsulfinyl)-3,4-dihydronaphthalen-1-yl triflate with 2-naphthylmagnesium bromide followed by trapping with carbon dioxide, the corresponding carboxylic acid was not obtained.

Footnote

Electronic supplementary information (ESI) available: Experimental procedures and characterization for new compounds including NMR spectra. See DOI: 10.1039/d0cc02788j

This journal is © The Royal Society of Chemistry 2020
Click here to see how this site uses Cookies. View our privacy policy here.